(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
24 July 2003 (24.07.2003)

PCT

(10) International Publication Number
WO 03/059950 A1

(51) International Patent Classification[7]: C07K 14/715

(21) International Application Number: PCT/IL02/01059

(22) International Filing Date:
31 December 2002 (31.12.2002)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
147414 31 December 2001 (31.12.2001) IL

(71) Applicant *(for all designated States except US)*: **YEDA RESEARCH AND DEVELOPMENT CO. LTD** [IL/IL]; At Weizmann Institute of Science, P.O.Box 95, 76100 Rehovot (IL).

(72) Inventor; and

(75) Inventor/Applicant *(for US only)*: **SCHREIBER, Gideon** [IL/IL]; Hashikma St. 21, P.O.Box 8464, 76331 Rehovot (IL).

(74) Agent: **EINAV, Henry**; Inter-Lab Ltd., Science based Industrial Park, 76100 Ness Ziona (IL).


(81) Designated States *(national)*: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States *(regional)*: ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:
— *with international search report*

[Continued on next page]

(54) Title: IFNAR2 MUTANTS, THEIR PRODUCTION AND USE



(57) Abstract: The present invention relates to mutant polypeptides of the beta chain of the type I IFN receptor (IFNAR2 mutant) with enhanced affinity for interferon-beta as compared to the wild type protein for prolonging the effect of IFN-beta in vivo.

WO 03/059950 A1

— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments*

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.